Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lobeglitazone - Chong Kun Dang

Next Previous
Drug Profile

Lobeglitazone - Chong Kun Dang

Alternative Names: CKD-501; Duvie; Lobeglitazone sulfate; M-107

Latest Information Update: 12 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chong Kun Dang
  • Developer Aclipse Therapeutics; Chong Kun Dang; EQUIS & ZAROO
  • Class Antihyperglycaemics; Gastrokinetics; Pyrimidines; Small molecules; Thiazolidinediones
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Phase I Gastroparesis

Most Recent Events

  • 07 Nov 2024 Aclipse Therapeutics plans a phase II trial for Gastroparesis in next year
  • 17 May 2024 Chong Kun Dang Pharmaceutical completes a phase I trial in Type 2 diabetes mellitus (In volunteers, Combination therapy) in South Korea (PO, Tablet) (NCT06483243)
  • 04 Apr 2024 Chong Kun Dang Pharmaceutical initiates enrolment in a phase I trial for Type 2 diabetes mellitus (In volunteers, Combination therapy) in South Korea (PO, Tablet) (NCT06483243)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top